|
|
Best Practices in Multiple Myeloma Care: Opportunities to Improve Outcomes in Community Settings
As nurses and APPs are well positioned to educate, support, and coordinate care for patients with multiple myeloma, having insight into the evolving trajectory of the disease will enhance their ability to provide quality patient care and identify and eliminate barriers. Addressing barriers to care remains key in ensuring access to novel therapies and improving quality of life. Having an understanding of the advances and increasing complexity of care of the patient with multiple myeloma will pr... |
|
|
Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa... |
|
|
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVITY DESCRIPTION
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ... |
|
|
Unmasking Multiple Myeloma and Its Precursor Conditions in Primary Care
For multiple myeloma (MM) patients to receive the most appropriate care, a quick and accurate diagnosis is paramount. This is especially the case for Black patients, as diagnosis has historically been slower in Black patients"even though MM is twice as common in Black Americans than in White Americans. Additionally, MM precursor conditions such as monoclonal gammopathy of undetermined significance are seen more frequently in Black Americans than in White Americans. Primary care providers ... |
|
|
Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma
As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administ... |
|